Connect with us

Biotechnology

U.K.’s RenalytixAI aims for dual listing with $86M Nasdaq IPO

Avatar

Published

on

The Cardiff, U.K.-based developer of artificial intelligence-based kidney diagnostics, RenalytixAI, is looking to become dual-listed on both the Nasdaq and London’s AIM stock exchange.

The two-year-old company filed this week for a new global offering and an $86 million U.S. IPO, under the Nasdaq ticker RNLX. RenalytixAI was previously listed in London under the symbol RENX, with a market cap of £303 million, or about $377 million U.S. according to Renaissance Capital.

At the same time, the company announced upcoming changes to its board, with its non-executive chair, Julian Baines, and non-executive director Richard Evans planning to step down before the completion of the Nasdaq dual-listing. Non-executive director Christopher Mills will become interim chair and oversee a search for replacement directors.

Whitepaper

How the fast-changing R&D pipeline is amplifying the importance of adaptable CROs

The story of CMIC’s rise from being a startup in a one-room apartment to a multinational leader is defined by an ability and readiness to foresee the changing needs of biopharma companies and adapt accordingly. With pipelines primed to continue evolving in the coming years, that adaptable approach is now more important than ever.

RenalytixAI has been developing algorithms that use proprietary blood-based biomarkers, genomic information and electronic health record data to derive an individual patient’s risk score for chronic kidney disease and progressive declines in function over five years, on a scale of 0 to 100. The company plans to launch its KidneyIntelX offering in the U.S. as well as the U.K., European Union and China.

RELATED: RenalytixAI scores $29M for AI-based kidney disease diagnostics

The company first licensed AI tech from the Icahn School of Medicine at Mount Sinai in May 2018. And by the third quarter of this year, RenalytixAI plans to begin a commercial launch and patient testing in partnership with Mount Sinai Health System, according to the company’s prospectus filed with the SEC.

Earlier this month, the company received approval from New York State Department of Health to provide commercial testing to state residents. With its CLIA laboratories in New York and Utah, RenalytixAI said it is now set up to provide testing services in 47 states, and expects to receive licenses for California, Maryland and Pennsylvania by the end of the year.

Read more on

Source: https://www.fiercebiotech.com/medtech/uk-s-renalytixai-aims-for-dual-listing-86m-nasdaq-ipo

Biotechnology

New patent for Optinose Us drug XHANCE

Avatar

Published

on

Copyright © DrugPatentWatch. Originally published at New patent for Optinose Us drug XHANCE

Annual Drug Patent Expirations for XHANCE
Annual Drug Patent Expirations for XHANCE

Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are sixteen patents protecting this drug.

XHANCE drug price trends.

This drug has two hundred and forty-five patent family members in twenty-eight countries.

The generic ingredient in XHANCE is fluticasone propionate. Additional details are available on the fluticasone propionate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Optinose Us drug XHANCE

Source: https://www.drugpatentwatch.com/blog/new-patent-for-optinose-us-drug-xhance/

Continue Reading

Biotechnology

New patent for Janssen Prods drug PREZCOBIX

Avatar

Published

on

Copyright © DrugPatentWatch. Originally published at New patent for Janssen Prods drug PREZCOBIX

Annual Drug Patent Expirations for PREZCOBIX
Annual Drug Patent Expirations for PREZCOBIX

Prezcobix is a drug marketed by Janssen Prods and is included in one NDA. It is available from one supplier. There are four patents protecting this drug.

PREZCOBIX drug price trends.

Drug patent litigation for PREZCOBIX.

This drug has two hundred and thirty-seven patent family members in thirty-nine countries.

The generic ingredient in PREZCOBIX is cobicistat; darunavir. One supplier is listed for this compound. Additional details are available on the cobicistat; darunavir profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Janssen Prods drug PREZCOBIX

Source: https://www.drugpatentwatch.com/blog/new-patent-for-janssen-prods-drug-prezcobix-14/

Continue Reading

Biotechnology

New patent for Janssen Pharms drug INVEGA SUSTENNA

Avatar

Published

on

Copyright © DrugPatentWatch. Originally published at New patent for Janssen Pharms drug INVEGA SUSTENNA

Annual Drug Patent Expirations for INVEGA+SUSTENNA
Annual Drug Patent Expirations for INVEGA+SUSTENNA

Invega Sustenna is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge.

INVEGA SUSTENNA drug price trends.

Drug patent litigation for INVEGA SUSTENNA.

This drug has twenty-four patent family members in seventeen countries.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. One supplier is listed for this compound. Additional details are available on the paliperidone palmitate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Janssen Pharms drug INVEGA SUSTENNA

Source: https://www.drugpatentwatch.com/blog/new-patent-for-janssen-pharms-drug-invega-sustenna/

Continue Reading
AI3 hours ago

5 Tips to Protect Your Online Store from Cybercriminals

AI5 hours ago

9 Business Applications for Seamless Internal Communications

Cleantech6 hours ago

Elon Musk: Private Beta Of Tesla Full Self Driving Hopefully In ~1 Month Or So

Crowdfunding6 hours ago

Overfunding: Pizza Brand @pizza Quickly Secures £820,000 Funding Target Through Crowdcube Campaign

Crowdfunding6 hours ago

Update: UK Banking Managing App RoosterMoney Now Nearing £2.1 Million Through Seedrs Funding Round

Crowdfunding7 hours ago

Sapiens Teams Up With GreenRoad Technologies to Improve Driver Safety & Personalized Driver Insurance Premiums

Cleantech7 hours ago

Support Climate Action or Win a Tesla? Why Not Both!

Cleantech9 hours ago

SEC: BMW Violated Anti-Fraud Provisions While Raising $18 Billion From Investors

Cleantech9 hours ago

Lordstown on the Electrification of Pickup Trucks — CleanTechnica Interview

Cleantech10 hours ago

EV Market Share Is Up, But What Is Still Holding Most People Back From Getting An EV?

Crowdfunding10 hours ago

Blockchain Firm ICONLOOP to Work with South Korea’s Pohang City, Steel Manufacturer POSCO, and Others on Supporting Decentralized ID Ecosystem

Blockchain10 hours ago

Willy Woo: Bitcoin to Decouple From Traditional Markets Soon

Crowdfunding10 hours ago

NYCE Tops $1 Million Using Reg CF on Two Different Funding Portals – Republic and Wefunder

Blockchain10 hours ago

Most crypto exchanges are vulnerable by design, says Bybit CEO

Cleantech10 hours ago

Cleantech Startup Nature Launches New Home Automation Device

CoinTelegraph10 hours ago

Why traders are not worried that the KuCoin hack will drop Ethereum price

Crowdfunding10 hours ago

Checkout.com, Pakistan’s National E-Commerce Council, and National Institutional Facilitation Technologies to Support Digital Payments in Country

Crowdfunding10 hours ago

Binance Might be Only Entity with Enough UNI Governance Tokens to Submit Uniswap Protoocol Proposals: Report

Cleantech11 hours ago

The Art Of Communicating Cleantech Risk

Cleantech11 hours ago

Electric Vehicles: The Dirty Nickel Problem

CoinTelegraph11 hours ago

Freeze, pause, reboot: Projects react differently to $200M KuCoin hack

Crowdfunding12 hours ago

Indonesian Regulators and Fintech Firms are Focused on Balancing Regulations with Responsible Innovation

Blockchain13 hours ago

Here’s how Bitcoin spot, derivatives will do, following the expiry

Blockchain13 hours ago

Woman Indicted on Bitcoin-Fueled Murder-for-Hire Charges

CoinTelegraph13 hours ago

Only 2.5 million Bitcoin left to mine

CoinTelegraph14 hours ago

Top 5 cryptocurrencies to watch this week: BTC, DOT, CRO, XEM, XTZ

Blockchain14 hours ago

Here’s Binance CEO’s take on how to ‘sort of slow down crypto-adoption’

Blockchain15 hours ago

Chainlink, FTX Token, Crypto.com Coin Price Analysis: 27 September

Blockchain15 hours ago

Bitcoin retail traders have a lot to lose if this happens

Blockchain16 hours ago

Ledger Calls Out KuCoin After Hack as Wallet Users Cry Foul

Blockchain16 hours ago

Chainlink medium-term Price Analysis: 27 September

Blockchain17 hours ago

Katal Chain: A Template for Blockchain-Based Finance

Cannabis19 hours ago

Investment and Securities Litigation – Handshake Deals Are Not. Your. Friend.

AR/VR19 hours ago

The VR Job Hub: Firesprite, Wookey & Ubisoft Reflections

Blockchain19 hours ago

Bitfinex CTO Defends the Freezing of Millions of USDT in Wake of KuCoin Hack

Blockchain20 hours ago

NORWEGIAN BLOCK EXCHANGE erbjuder kunder i Sverige kryptovaluta på ett tillförlitligt sätt

AI21 hours ago

Are You Prepared for the Tech Professions of Tomorrow?

Blockchain24 hours ago

Data Gumbo Chief Talks Saudi Aramco Backing and Latest $4M Round

Blockchain1 day ago

The Bahamas to Begin Gradual Launch of World’s First CBDC in October

Blockchain2 days ago

Justin Sun Reduces SUN Mining Output, Expects ‘Positive Impact’

Trending